Glioblastoma in natalizumab-treated multiple sclerosis patients

被引：9

作者：

Morales, Fabian Sierra ^{[1
,2
,3
]}

Wright, Robert B. ^{[2
]}

Novo, Jorge E. ^{[4
]}

Arvanitis, Leonidas D. ^{[4
]}

Stefoski, Dusan ^{[2
,3
]}

Koralnik, Igor J. ^{[1
,2
]}

机构：

[1] Rush Univ, Med Ctr, Sect Neuroinfect Dis, Chicago, IL 60612 USA

[2] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA

[3] Rush Univ, Med Ctr, Multiple Sclerosis Ctr, Chicago, IL 60612 USA

[4] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA

来源：

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY | 2017年 / 4卷 / 07期

基金：

美国国家卫生研究院;

关键词：

NERVOUS-SYSTEM LYMPHOMA; LONG-TERM SAFETY; MELANOMA; RISK;

D O I：

10.1002/acn3.428

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade II astrocytoma. He is still alive 5 years after the diagnosis of GBM. JC virus was not detected in either case. Whether natalizumab played a role in the development of GBM in those patients deserves further investigation.

引用

页码：512 / 516

页数：5

共 23 条

[1] Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?
Bergamaschi, Roberto
Montomoli, Cristina
[J]. MULTIPLE SCLEROSIS, 2009, 15 (12): : 1532 - 1533
[2] β1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma
Carbonell, W. Shawn
Delay, Michael
Jahangiri, Arman
Park, Catherine C.
Aghi, Manish K.
[J]. CANCER RESEARCH, 2013, 73 (10) : 3145 - 3154
[3] Multiple sclerosis
Compston, Alastair
Coles, Alasdair
[J]. LANCET, 2008, 372 (9648) : 1502 - 1517
[4] Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Fadul, Camilo E.
Fisher, Jan L.
Hampton, Thomas H.
Lallana, Enrico C.
Li, Zhongze
Gui, Jiang
Szczepiorkowski, Zbigniew M.
Tosteson, Tor D.
Rhodes, C. Harker
Wishart, Heather A.
Lewis, Lionel D.
Ernstoff, Marc S.
[J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (04) : 382 - 389
[5] Subsequent brain tumors in patients with autoimmune disease
Hemminki, Kari
Liu, Xiangdong
Forsti, Asta
Ji, Jianguang
Sundquist, Jan
Sundquist, Kristina
[J]. NEURO-ONCOLOGY, 2013, 15 (09) : 1142 - 1150
[6] CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS
Hofer, Silvia
Linnebank, Michael
Weller, Michael
[J]. NEUROLOGY, 2010, 74 (07) : 614 - 615
[7] Genetic characterization of gliomas arising in patients with multiple sclerosis
Khalil, Adam
Serracino, Hilary
Damek, Denise M.
Ney, Douglas
Lillehei, Kevin O.
Kleinschmidt-DeMasters, B. K.
[J]. JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (02) : 261 - 272
[8] The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years
Korshunov, A
Sycheva, R
Golanov, A
[J]. CANCER, 2005, 104 (04) : 825 - 832
[9] Association of melanoma and natalizumab therapy in the Italian MS population: a second case report
Laroni, A.
Bedognetti, M.
Uccelli, A.
Capello, E.
Mancardi, G. L.
[J]. NEUROLOGICAL SCIENCES, 2011, 32 (01) : 181 - 182
[10] Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab
Law, Jennie Y.
Kim, Dong W.
Sturgis, Ariel
Naina, Harris V.
[J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 61 - 63

← 1 2 3 →